年龄对晚期肢体恶性肿瘤隔离肢体灌注疗效的影响
该研究基于2005年1月至2018年1月单中心前瞻性数据库,纳入179例成功行隔离肢体灌注(ILP)的晚期肢体恶性肿瘤患者,按年龄<75岁与≥75岁分层,比较围手术期并发症、局部区域毒性、缓解率及肿瘤学结局。结果显示两组灌注成功率、严重局部毒性和围手术期并发症或死亡率无差异,老年患者疗效与安全性可比。
要点
- ≥75岁与<75岁患者ILP的灌注成功率、严重局部区域毒性及围手术期并发症或死亡率无差异
- 黑色素瘤总体缓解率82.4%,软组织肉瘤总体缓解率63.5%,两年龄组间缓解率无差异
- <75岁软组织肉瘤患者局部无复发生存期较长(13个月对6个月),可能与年轻组化疗敏感亚型较多有关
核心结论
- ILP是老年晚期肢体恶性肿瘤的有效治疗,缓解率和毒性与年轻患者相当。
研究设计与样本
- 单中心前瞻性维护数据库研究,2005年1月至2018年1月共尝试189次灌注,179例成功灌注,技术成功率94.7%。
- 按病理(黑色素瘤、软组织肉瘤、其他)和年龄(<75岁、≥75岁)分层。
主要发现
- <75岁与≥75岁患者在灌注成功率、严重局部区域毒性、围手术期并发症或死亡率方面无差异。
- 黑色素瘤总体缓解率82.4%,两年龄组间缓解率及肿瘤学结局无差异。
- 软组织肉瘤总体缓解率63.5%,两年龄组间缓解率无差异;<75岁患者局部无复发生存期长于老年患者(13个月对6个月)。
关键数值与推荐
- 黑色素瘤总体缓解率82.4%。
- 软组织肉瘤总体缓解率63.5%。
- <75岁软组织肉瘤患者局部无复发生存期13个月,≥75岁为6个月。
临床怎么用
- 对≥75岁、不适合保肢手术的晚期肢体恶性肿瘤患者,ILP的疗效与安全性与年轻患者相当,可考虑应用。
- 软组织肉瘤年轻患者局部无复发生存期较长,可能与化疗敏感亚型较多有关,老年患者需个体化评估。
局限性
- 单中心回顾性分析前瞻性数据库,样本量有限(179例成功灌注),年龄分层比较可能受病理亚型分布影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Isolated limb perfusion (ILP) is a well-established treatment for patients with advanced extremity malignancies unsuitable for limb-conserving surgery. However, little is known about the outcomes of this treatment in elderly patients. We sought to determine the effects of age on the tolerability and efficacy of ILP for advanced extremity malignancy. PATIENTS AND METHODS: Patients undergoing ILP at our institution between January 2005 and January 2018 were identified from a prospectively maintained database. Patients were stratified by pathology (melanoma, soft-tissue sarcoma, other) and age (<75 years and ≥75 years). Outcomes of interest were perioperative morbidity and mortality, locoregional toxicities, response rates and oncological outcomes. RESULTS: During the study period, a total of 189 perfusions were attempted. Successful perfusions were performed in 179 patients, giving a technical success rate of 94.7%. No difference in perfusion success rates, severe locoregional toxicity and perioperative morbidity or mortality was noted between those aged <75 years and ≥75 years. The overall response rate in melanoma was 82.4%, and no difference in response rates or oncological outcomes between age groups was noted in these patients. The overall response rate in soft-tissue sarcoma was 63.5%, with no difference in response rates noted between age groups. However, patients aged <75 years with soft-tissue sarcoma had prolonged local recurrence-free survival compared with older patients (13 versus 6 months), possibly due to the prevalence of chemosensitive subtypes in the younger age group. CONCLUSION: ILP is an effective treatment for advanced extremity malignancies in the elderly, with comparable response rates and toxicities to younger patients.
引用
- Smith HG, Wilkinson MJ, Smith MJF, et al. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies. Eur J Cancer. 2018. PMID: 29940423. doi:10.1016/j.ejca.2018.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。